FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track
Phase 2a six-month progression-free survival exceeded the protocol-defined historical benchmark, but accelerated approval remains only a potential pathway.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NeOnc Technologies Holdings (NASDAQ: NTHI) secured an FDA meeting for early January 2027 to discuss potential accelerated approval of experimental NEO100.
The company seeks feedback on a 505(b)(2) New Drug Application for recurrent or progressive IDH-mutant grade 4 astrocytoma. Phase 2a six-month progression-free survival was 48.9% versus a protocol-defined 20% historical benchmark; the analysis included 24 patients with IDH1-mutant tumors, including 21 with grade 4 disease. No treatment-related Grade 3 or higher adverse events, serious adverse events or treatment discontinuations were reported.
NeOnc proposes a randomized Phase 3 comparison with investigator-selected standard chemotherapy, using overall survival as the primary endpoint. Updated NEO100 and NEO212 data are expected November 13, 2026; a separate NEO212 FDA meeting is scheduled November 17, 2026. NEO100's accelerated approval pathway remains under discussion.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointSix-month progression-free survival of 48.9% exceeded the protocol-defined 20% historical benchmark; one-sided p-value was 0.0047.
- Moderate pointNEO100 FDA meeting secured for early January 2027 to discuss a potential accelerated approval pathway.
- Minor pointNo treatment-related Grade 3 or higher adverse events, serious adverse events or treatment-related discontinuations were reported.
- Minor pointFive patients remained on treatment at the June 24, 2026 interim database lock.
- Minor point. Forward-looking: it has not happened yet and may not happen.Proposed Phase 3 trial would compare NEO100 with investigator-selected standard chemotherapy, measuring overall survival.
4 minor points
- Minor point160,016 shares purchased by Heshmatpour and Chen for approximately $629,000 using personal funds following Phase 2a results.
- Minor point80,000 additional shares purchased by Heshmatpour for approximately $269,082 across November 5, 6 and 9.
- Minor point. Forward-looking: it has not happened yet and may not happen.Updated NEO100 Phase 1/2a and NEO212 Phase 1 data expected at the November 13, 2026 neuro-oncology meeting.
- Minor pointNEO212 FDA End-of-Phase 1 meeting scheduled for November 17, 2026.
Negative
- Moderate pointPotential accelerated approval pathway requires FDA feedback on whether existing clinical and nonclinical evidence could support an application.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Confirming clinical benefit would rely on the proposed Phase 3 trial's final overall survival analysis.
- Minor pointPhase 2a efficacy analysis included 24 patients; the 48.9% result had a 95% confidence interval of 26.3%–68.1%.
- Minor pointProposed scientific bridge between published perillyl alcohol data and proprietary intranasal NEO100 remains a regulatory discussion topic.
Key Figures
- FDA meeting timing
- Early January 2027
- Scheduled Type B End-of-Phase meeting for NEO100
- PFS-6 rate
- 48.9%
- Phase 2a results; compared with a 20% historical benchmark
- 95% confidence interval
- 26.3% to 68.1%
- Reported for the Phase 2a PFS-6 rate
- One-sided p-value
- 0.0047
- Phase 2a PFS-6 result
- Efficacy analysis population
- 24 patients (21 with grade 4 disease)
- Patients with IDH1-mutant tumors
Historical Context
-
Phase 2a NEO100 reported PFS-6 of 48.9% against the 20% benchmark.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
505(b)(2) new drug application regulatory
accelerated approval regulatory
progression-free survival medical
overall survival medical
breakthrough therapy designation regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
DENVER, Nov. 11, 2026 (GLOBE NEWSWIRE) -- (247MarketNews) — NeOnc Technologies Holdings (NASDAQ: NTHI) secured a Type B End-of-Phase meeting, scheduled for early January 2027, with the U.S. Food and Drug Administration (FDA), to discuss a potential accelerated approval pathway for its experimental intranasal brain cancer treatment NEO100, putting the company's regulatory strategy in focus as it prepares for a randomized Phase 3 study.
NeOnc intends to seek FDA feedback on whether its existing clinical and nonclinical evidence could support a 505(b)(2) New Drug Application (NDA) seeking accelerated approval for recurrent or progressive IDH-mutant grade 4 astrocytoma.
The company also plans to discuss NEO100-012, a proposed multicenter, randomized, controlled Phase 3 trial comparing NEO100 against investigator's-choice standard-of-care chemotherapy. Overall survival would serve as the primary endpoint.
Phase 2a results provide the foundation for the FDA discussion
The company's accelerated approval ambitions follow results announced August 12, 2026, from the Phase 2a portion of its NEO100-01 study.
According to NeOnc, the study achieved a six-month progression-free survival (PFS-6) rate of
The efficacy analysis included 24 patients with IDH1-mutant tumors, 21 of whom had grade 4 disease. Five patients remained on treatment at the interim database lock on June 24, 2026.
NeOnc also reported that independent central MRI assessments were used and that no treatment-related Grade 3 or higher adverse events, treatment-related serious adverse events, or discontinuations due to treatment-related adverse events had occurred.
These results offer an encouraging signal, particularly given the limited treatment options available to patients with recurrent high-grade astrocytoma.
Why the accelerated approval strategy matters
The FDA's Accelerated Approval Program allows certain treatments for serious conditions to receive earlier approval based on a surrogate endpoint or intermediate clinical endpoint reasonably likely to predict clinical benefit.
For cancer treatments, progression-free survival can potentially serve as an endpoint supporting regulatory consideration, depending on the disease, treatment effect and strength of the supporting evidence.
NeOnc's NEO100-012 may be underway, with enrollment ongoing, when any potential NDA is submitted. The trial's final overall survival analysis would then be intended to confirm clinical benefit and support conversion to traditional approval.
A separate question concerns the company's proposed scientific bridge between published perillyl alcohol data and its proprietary intranasal NEO100 formulation.
The FDA is also expected to discuss the adequacy of the existing nonclinical safety package and whether NEO100 could qualify for Breakthrough Therapy designation.
Insider purchases add another dimension
There is also a notable corporate insider development worth considering.
In its November 5, 2026, third-quarter business update, NeOnc reported that Executive Chairman and CEO Amir Heshmatpour and Dr. Thomas C. Chen purchased a combined 160,016 shares of company common stock for approximately
Heshmatpour has continued buying shares in the open market, purchasing 80,000 shares for approximately
The latest purchases bring Heshmatpour's reported 2026 open-market buying to 271,000 shares, representing approximately
Short interest points a squeeze setup
Insider buying can provide an additional indication of management confidence, particularly when executives purchase shares in the open market rather than receiving equity compensation.
Market data for October 30, 2026, showed approximately 920,631 shares sold short, representing approximately 7.03 days to cover, well above the coveted 5 days to cover threshold, and several sites are reporting even larger amounts, which could be an even more powerful force.
November and January bring important catalysts
The FDA meeting is not the company's only upcoming milestone.
NeOnc announced in its November 5 third-quarter update that it expects to present updated NEO100 Phase 1/2a results and NEO212 Phase 1 data at the Society for Neuro-Oncology's annual meeting on November 13, 2026.
The NEO100 presentation will include updated results from the clinical study and compassionate-use experience.
Additional information from these presentations could help investors assess whether the August topline findings remain consistent with the updated clinical dataset.
The company also has a separate regulatory milestone involving NEO212, its oral investigational drug candidate. An FDA End-of-Phase 1 Type B meeting concerning NEO212 is scheduled for November 17, 2026, according to the company's September announcement.
For NEO100, the early January 2027 meeting will be the next major regulatory event, with the company saying it expects to provide an update after receiving and reviewing the FDA's official meeting minutes, as the content of those minutes could be more important than the announcement that the meeting itself has been scheduled.
About 247MarketNews
In today's fast-moving markets, visibility is everything and 247MarketNews provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 247MarketNews delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 247MarketNews can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247MarketNews is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247MarketNews highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
247MarketNews
Editor@247marketnews.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.